WEST LAFAYETTE, Ind., April 1, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates and companion imaging diagnostics for personalized therapy, announced today that three poster presentations will be presented by Endocyte scientists at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) to be held in Orlando, Florida, April 2-6, 2011.
"Two of our presentations disclose new therapeutic data from preclinical studies of our lead clinical compound, EC145. We recently completed a Phase 2 trial of EC145 in platinum resistant ovarian cancer and will be initiating a Phase 3 trial in the next few months," said Christopher P. Leamon, Ph.D., vice president of research. "Results from our detailed structure activity studies confirmed that EC145 is the most potent folate-vinca alkaloid conjugate produced to date, and it can be safely dosed in combination with many existing and approved anticancer agents, including cisplatin and docetaxel, to achieve greater therapeutic activity. In addition, a third presentation details a novel proprietary strategy for synthesizing a natural product toxin which is amenable for targeted drug applications."
Presentations are as follows:
Monday, April 4, 2011, 1:00 - 5:00 PM ET
- Abstract #2570, "Combination studies of EC145 with approved anti-cancer drugs for Ovarian Cancer" (Section 27, Board 26).
- Abstract #2518, "Structure-Activity Relationships of Folate-Vinca Alkaloid Conjugates" (Section 26, Board 3).
- Abstract #3259, "An Efficient Total Synthesis of Tubulysin B" (Section 16, Board 23).
About Endocyte
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve significant risks and uncertainties that may cause results to differ materially from those set forth in the statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: Stephanie Ascher Stern Investor Relations, Inc. (212) 362-1200 stephanie@sternir.com Tony Russo, Ph. D. Russo Partners (212) 845 4251 tony.russo@russopartnersllc.com